Cascadian Therapeutics Inc (NASDAQ:CASC) saw a large decrease in short interest in the month of January. As of January 12th, there was short interest totalling 818,899 shares, a decrease of 36.2% from the December 29th total of 1,282,670 shares. Based on an average daily volume of 324,030 shares, the days-to-cover ratio is currently 2.5 days. Approximately 2.0% of the company’s shares are short sold.
A number of institutional investors have recently modified their holdings of the stock. OxFORD Asset Management LLP raised its stake in Cascadian Therapeutics by 11.8% during the 2nd quarter. OxFORD Asset Management LLP now owns 181,323 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 19,131 shares during the period. SG Americas Securities LLC raised its stake in Cascadian Therapeutics by 194.7% during the 4th quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 25,464 shares during the period. New York State Common Retirement Fund acquired a new stake in Cascadian Therapeutics during the 2nd quarter worth $136,000. Rhumbline Advisers acquired a new stake in Cascadian Therapeutics during the 2nd quarter worth $143,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Cascadian Therapeutics during the 2nd quarter worth $225,000. 80.33% of the stock is currently owned by institutional investors and hedge funds.
Separately, Zacks Investment Research downgraded Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.63.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same period last year, the company posted ($0.09) EPS. equities research analysts predict that Cascadian Therapeutics will post -1.27 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Cascadian Therapeutics Inc (CASC) Short Interest Down 36.2% in January” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/29/cascadian-therapeutics-inc-casc-short-interest-down-36-2-in-january.html.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.